The global lupus nephritis treatment market, valued at USD 2 billion in 2023, is set to experience significant growth, reaching an estimated market value of USD 5.67 billion by 2033. This expansion reflects a compound annual growth rate (CAGR) of 11% during the forecast period from 2023 to 2033.
Several factors contribute to this upward trajectory, including the rising incidence of lupus nephritis, an autoimmune disease that primarily affects the kidneys, as well as increased awareness surrounding the condition. The growing recognition of lupus nephritis has led to a surge in demand for treatments that can effectively manage and alleviate the symptoms of the disease. Furthermore, the market is benefiting from the emergence of novel therapies that offer innovative treatment options, improving patient outcomes and driving the demand for advanced care.
The market has already demonstrated a promising growth rate of 6.5% CAGR in the historical period from 2018 to 2022, indicating a solid foundation for continued expansion. With a growing number of treatment options and greater understanding of the disease, the lupus nephritis treatment market is poised for substantial development over the next decade.
As the healthcare landscape continues to evolve, companies within the lupus nephritis treatment sector are encouraged to innovate and collaborate, ensuring the delivery of effective and groundbreaking therapies to address the needs of patients worldwide.
Key Takeaways from the Market Study:
- The Lupus nephritis treatment market is expected to grow at a value of 11% CAGR in the foreast period 2023 to 2033
- Hospital pharmacies are expected to hold 45% of the market share in 2023 for Lupus nephritis treatment market.
- North America is expected to possess 44% market share for Lupus nephritis treatment market in 2023.
- Europe Lupus nephritis treatment market size is expected to possess 40% market share in 2023.
“Researchers and pharmaceutical companies are continuing to develop new and innovative therapies for lupus nephritis. This, in turn, is contributing to growth of the market.” states an FMI analyst
Surge in Market Needs: Discover Comprehensive Analysis and Insights in Our Detailed Report!
Competitive Landscape:
Key players in the lupus nephritis treatment are Roche, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, AstraZeneca, Aurinia Pharmaceuticals Inc., Johnson & Johnson Private Limited, Bayer AG, Sanofi, Sun Pharmaceutical Industries Ltd and Abbott
- BMS has sponsored several clinical trials focused on developing treatments for lupus nephritis. For example, the company is currently sponsoring a Phase III clinical trial to investigate the efficacy and safety of abatacept in combination with mycophenolate mofetil (MMF) in patients with lupus nephritis.
- In 2021, Eli Lilly announced positive results from a Phase 3 clinical trial of Olumiant in patients with lupus nephritis. The trial showed that Olumiant, in combination with standard-of-care treatment, significantly improved kidney function compared to standard-of-care treatment alone. Based on these results, Eli Lilly has submitted an application for regulatory approval of Olumiant as a treatment for lupus nephritis.
Key Segments Profiled in the Lupus Nephritis Treatment Market Survey:
Drug Class:
- Corticosteroids
- Immunosuppressive
- Azathioprine
- Cyclophosphamide
- Mycophenolate
- Belimumab
Route of Administration:
- Oral
- Parenteral
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube